Oncology and Carcinogenesis articles for Huazhong University of Science and Technology (HUST), China

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 113

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
7 4.29
Ferritin-Based Mild Magnetic Hyperthermia Therapy for Bladder Cancer: A Synergistic Anti-Inflammatory Strategy 0.14
A Self-Assembled Irinotecan Nanomedicine Abrogates Steatohepatitis-Induced Liver Metastasis and Potentiates Antitumor Efficacy against Colorectal Cancer 1.00
Noncontact Environmental Radiation Sensitization via Photoresponse Processes Mediated by Nanostructured Ru-Based Photosensitizers with Near-Infrared Responsiveness 0.09
Surface d-Band Modulation via Biodirected Mineralization Enables Nanoenzymes to Inhibit Radiation-Induced T-Cell Exhaustion and Potentiate Immunoradiotherapy 1.00
Immune-Modulating Dual-Targeted Nanomaterials for Low-Temperature Photothermal–Photodynamic–Chemodynamic Therapy of Osteosarcoma Targeting Tumor and Endothelial Cells 0.78
NO-Driven Self-Propelled Nanomotors Augment Chemo-Immunotherapy and Transcatheter Arterial Embolization 0.33
Thermosensitive Resiquimod-Loaded Lipid Nanoparticles Promote the Polarization of Tumor-Associated Macrophages to Enhance Bladder Cancer Immunotherapy 0.94
3 2.30
A Modular DNA Hydrogel Vaccine with Optimized Nanoadjuvants and Tumor Targeting Capacity 1.00
Ambient Laser Writing of Strongly Coupled High-Entropy Alloy Nanohybrids for Peroxide Electrocatalysis and On-Chip Dual-Mode Sensing 0.50
Electric‐Field‐Mediated In Situ Electrocatalysis for Enhanced Chemodynamic Therapy and Immunotherapy via 3D Electrode Arrays 0.80
1 0.61
Peptide Coacervates with Metal–Phenolic Membranes Modulate Glucose Metabolism and Enhance Cancer Immunotherapy 0.61
1 1.00
Targeting CDH2 and TUBA1A in Neuroblastoma Bone Marrow Metastasis: Insights from Single-Cell Analysis and Drug Screening 1.00
1 0.22
Microfluidics-Based High-Throughput Single-Cell Analysis of Reactive Oxygen Species and T Cell Exhaustion 0.22
1 0.44
Reactive Oxygen Species-Responsive Biomimetic Nanoplatelets for Thrombus-Mediated Photothermal Immunotherapy of Tumor 0.44
1 0.96
BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis 0.96
1 0.01
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies 0.01
3 0.12
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial 0.03
Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases 0.04
Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study 0.04
5 3.25
Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion 0.90
Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma 0.02
Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer 0.59
Exon Skipping of Ste20-Like Kinase Enhances Glycolysis and Tumor Progression by Activating Enolase 1-Mediated Phosphoenolpyruvate Production. 1.00
A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer 0.73
1 0.72
Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis 0.72
2 0.22
Serotonin-licensed macrophages potentiate chemoresistance via inositol metabolic crosstalk in ovarian cancer 0.06
Arachidonic acid triggers spermidine synthase secretion from primary tumor to induce skeletal muscle weakness upon irradiation 0.16
1 0.06
Rationally designed sonocatalyst-enhanced supramolecular ferroptosis inducers for effective cancer therapy 0.06
1 0.05
Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy 0.05
2 1.48
Hypoxia-related and immune phenotype-related fusion model for non-invasive prognostication of hepatocellular carcinoma treated by TACE: a multicentre study 0.48
Targeting Aurora kinase B regulates cholesterol metabolism and enhances chemoimmunotherapy in cholangiocarcinoma 1.00
2 0.92
Targeting mTORC2-Dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and β-catenin-mutated hepatocellular carcinoma. 0.02
NEK7 induced phosphorylation of EGFR on serine 1070 drive the acquired lenvatinib resistance in hepatocellular carcinoma. 0.90
1 0.25
Mechanical signaling via β2 integrin decouples T cell proliferation and differentiation for generating stem cell-like CAR T cells 0.25
4 1.67
The cyclin-dependent kinase inhibitor p27 facilitates chemosensitivity by promoting ferroptosis in epithelial ovarian cancer 0.93
NITAC-mediated ISGylation of eIF4E2 attenuates GSK3β proline-directed kinase activity, conferring cytoprotection 0.15
USP52 inhibits cell ferroptosis via Hippo–YAP pathway and blocks immunotherapy in colorectal cancer 0.02
The long noncoding RNA SNHG12 defines KEAP1 stability and ferroptosis susceptibility by targeting E3 ligase TRIM25 0.57
6 3.34
IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor-induced inflammatory arthritis 0.03
Tumor cell–derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance 0.96
Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models 0.15
HDAC5 deficiency induces intrinsic resistance to KRAS inhibition by disrupting c-Myc acetylation-ubiquitination homeostasis 1.00
IL-17-producing γδ T cells in the tumor microenvironment promote radioresistance in mice 0.93
Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop 0.27
4 0.17
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. 0.08
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. 0.03
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study. 0.03
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. 0.03
1 0.97
Adenosine metabolic clearance maintains liver homeostasis by licensing arginine methylation of RIPK1 0.97
1 0.02
Distinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression 0.02
2 0.30
A Spatially Controllable DNA Origami-Based T-Cell Cluster Engager for Precise Tumor Elimination 0.20
Regioisomeric Engineering of Sterically Hindered Bright Near-Infrared Paraptosis Agents for Chemo-Photodynamic Therapy 0.10
1 0.01
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.01
1 0.18
Glucose-1-phosphate promotes compartmentalization of glycogen with the pentose phosphate pathway in CD8+ memory T cells 0.18
1 0.07
Spatiotemporally Ultrasound-Activatable Self-Amplifying Biomimetic Liposomes for Imaging-Guided Synergistic Cancer Sonodynamic Chemotherapy 0.07
1 0.23
SLC2A1+ tumour-associated macrophages spatially control CD8+ T cell function and drive resistance to immunotherapy in non-small-cell lung cancer 0.23
1 0.21
IDO1 regulating ROS rhythm reveals glycogenolysis/PPP as a cancer treatment target 0.21
27 12.08
Iron overload in the tumor microenvironment induces CD8+ T cell ferroptosis and dysfunction 0.05
ACAD8 deficiency promotes pathological cardiac hypertrophy in response to pressure overload by regulating histone isobutyrylation 0.15
Disrupting sympathetic nerve-tumor crosstalk via biomimetic nanovesicles to augment chemotherapy efficacy under chronic stress 0.97
Hijacking innate immunity to enhance mRNA therapeutics by blocking IFN-P-body-XRN1 axis-mediated degradation 0.08
Multitrait GWAS and functional validation reveal genetic loci for gastric cancer 0.05
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial 0.02
An ultraconserved pseudo 5’ splice site fine-tunes development by regulating alternative splicing within TOR-related pathways 0.05
A neurotoxic cryptic peptide arising from TDP-43-dependent cryptic splicing of 0.42
cfGWAS reveal genetic basis of cell-free DNA end motifs 0.06
Hepatocytes functionally reprogrammed by KIAA1199-high colorectal cancer cells favour the accumulation of pro-metastatic Egr1+ neutrophils 0.85
Disruption of iron homeostasis sensitizes pancreatic cancer to irreversible electroporation 1.00
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial 0.06
Hypoxia-driven remodeling of SELENOP macrophages shapes T cell dynamics and promotes ovarian cancer metastasis 0.22
Targeting SPAK suppresses progression and averts an immune exhaustive microenvironment in hepatocellular carcinoma 0.95
USP10 promotes glioma stem cell maintenance and glioblastoma growth by antagonizing DTX3L-mediated SATB2 ubiquitination 0.11
Peptide-functionalized membrane camouflage for endogenous HS-induced photothermal immunotherapy of orthotopic colorectal cancer 0.80
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial 0.03
Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial 0.79
USP29 and SMURF1 orchestrate FSP1-mediated ferroptosis suppression to facilitate chemoresistance in gastric cancer 0.28
Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination 0.89
A glucose kinase-independent HK2 activity prevents TNF-induced cell death by phosphorylating RIPK1 0.97
VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization 1.00
Stabilizing a mammalian RNA thermometer confers neuroprotection in subarachnoid hemorrhage 0.24
Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis 0.01
Living therapeutics of nonpathogenic bacteria as biosynthesis factory and active carriers for enhancing tumor-targeted therapy 1.00
Regulation of partial endothelial-to-mesenchymal transition by circATXN1 in ischemic diseases 0.06
DDX1 methylation mediated MATR3 splicing regulates intervertebral disc degeneration by initiating chromatin reprogramming 1.00
1 0.11
Succinate drives gut inflammation by promoting FOXP3 degradation through a molecular switch 0.11
3 0.88
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study 0.85
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial 0.00
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial 0.03
1 0.05
Architecture of the human KICSTOR and GATOR1–KICSTOR complexes 0.05
2 1.63
Stelleroids A–C, Three Rearranged Guaiane Sesquiterpenoids with Caged Ring Systems from Stellera chamaejasme 0.63
Scabrosteroids A–D, Four Pyrrolidinone–Ergosterol Heterodimers from Penicillium scabrosum FXI744 1.00
1 0.83
CUL5 E3 ubiquitin ligase regulates the evasion of bladder cancer cells to CD8+ T cell-mediated killing by inhibiting autophagy 0.83
1 0.13
Reciprocal regulation of TNF receptor 1–mediated signaling and inflammatory damages by MARCH2 and USP22 0.13
2 1.04
Disrupting USP14-mediated PARP1 dynamics reinstates MIC-A/B–driven antigen-independent CD8+ T cell killing in glioma 0.70
Targeting lipid scrambling potentiates ferroptosis and triggers tumor immune rejection 0.34
4 2.02
Genomic instability drives POSTN+ myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer 0.91
Phase separation–based HTS identifies cobimetinib as a YAP-TEAD inhibitor that suppresses hyperactivated YAP-induced cancer progression 0.05
Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer 0.90
Targeted suppression of glioma by ultralow-dose x-ray–induced photodynamic therapy and gold-based nanoclusters in preclinical models 0.16
2 0.04
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial 0.03
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial 0.01
4 0.11
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial 0.03
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial 0.02
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China 0.03
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial 0.03
6 0.23
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study 0.04
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial 0.05
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study 0.04
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study 0.03
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial 0.04
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial 0.02
2 0.06
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy 0.02
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.03

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.